U.S. markets closed
  • S&P Futures

    3,696.75
    +26.75 (+0.73%)
     
  • Dow Futures

    29,541.00
    +198.00 (+0.67%)
     
  • Nasdaq Futures

    11,407.75
    +91.50 (+0.81%)
     
  • Russell 2000 Futures

    1,678.00
    +15.50 (+0.93%)
     
  • Crude Oil

    77.31
    +0.60 (+0.78%)
     
  • Gold

    1,638.90
    +5.50 (+0.34%)
     
  • Silver

    18.50
    +0.02 (+0.14%)
     
  • EUR/USD

    0.9628
    +0.0017 (+0.17%)
     
  • 10-Yr Bond

    3.8780
    +0.1810 (+4.90%)
     
  • Vix

    32.26
    +2.34 (+7.82%)
     
  • GBP/USD

    1.0749
    +0.0066 (+0.61%)
     
  • USD/JPY

    144.5520
    -0.1280 (-0.09%)
     
  • BTC-USD

    19,776.37
    +888.72 (+4.71%)
     
  • CMC Crypto 200

    453.75
    +20.65 (+4.77%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,614.79
    +183.24 (+0.69%)
     

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

·1 min read
EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc.

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

  • H.C. Wainwright 24th Annual Global Investment Conference
    Forum: Corporate Presentation
    Date: Monday, September 12, 2022
    Time: 7:00 a.m. ET

  • Baird 2022 Global Healthcare Conference
    Forum: Corporate Presentation
    Date: Wednesday, September 14, 2022
    Time: 1:25 p.m. ET

  • Guggenheim Nantucket Therapeutics Conference
    Forum: Fireside Chat
    Date: Thursday, September 29, 2022
    Time: 10:30 a.m. ET

  • Benzinga Retail Conference (Virtual)
    Forum: Fireside Chat
    Date: Friday, September 30, 2022
    Time: 11:40 a.m. ET

A webcast and subsequent archived replay of the corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com